JVIR Celebrates 25 Years of Innovation. Part 5: 2011–2015

JVIR Celebrates 25 Years of Innovation. Part 5: 2011–2015

JVIR HISTORY JVIR Celebrates 25 Years of Innovation. Part 5: 2011–2015 Tony P. Smith, MD, FSIR In an Editorial titled “JVIR: At the Vanguard” (1), Dr...

1MB Sizes 0 Downloads 14 Views


JVIR Celebrates 25 Years of Innovation. Part 5: 2011–2015 Tony P. Smith, MD, FSIR In an Editorial titled “JVIR: At the Vanguard” (1), Dr. Ziv Haskal (Fig 1), the fifth editor of the Journal of Vascular and Interventional Radiology, wrote: It is the journal’s job to carry and maintain the standard—thus, my role has two audiences. For the readers, I pledge to ensure the continued excellence of material we publish, to help progressively move our science to prospective clinical and basic research, and to encourage vigorous discourse regarding it. … For the authors, I pledge to provide you with a rapid and fair review process. Dr. Haskal noted in that same editorial a theme that, more than any other, defined the upcoming years: “JVIR understands that we are in a different information era than a decade ago. To that end, we plan to expand the ways JVIR provides you the information you need through a number of endeavors.” Those endeavors in essence have been the bringing of JVIR into the age of electronic advancement. With the January 2011 edition, a new cover with a more global format was introduced (Fig 2), and a new layout and website were completed during that first year. JVIR. org became customizable, and article access was vastly improved. JVIR (iTunes) podcasts, e-subscriptions for Latin America, extension of the trainee reviewer program to residents and medical students (with faculty mentors), and the promise of “JVIR Fast” became reality. The turnaround times from initial submission to first editorial decision became well under the 30-day goal initially set by Dr. Haskal—and have been maintained since. Submissions rapidly increased and are now nearly double those of 2010 (2). Invited commentaries on selected articles were first published in 2011 and have become a popular regular feature as have the more pictorial Images in IR and Extreme IR as well as video articles. Case reports shifted

more to concise Letters, allowing more to be published. JVIR now even publishes the occasional cartoon. Over the past 4 years, JVIR has expanded widespread use of online supplements and appendices, providing limitless additional videos, tables, study questionnaires, and statistical and raw data to be shared outside of the concise in-print articles. The JVIR iPad App debuted in an Editorial by Dr Haskal in October 2012 (3). A broad social media strategy rolled out in 2014, including Twitter, Facebook, Instagram, and the JVIR Access blog, providing different aspects of JVIR and its availability anywhere one can access the World Wide Web. When asked about less public goals for the journal, Haskal answered: Several major ones: First, to establish JVIR as a premier destination on par with the world’s top tier

From the Division of Peripheral and Neurological Interventional Radiology, Department of Radiology, Duke University Medical Center, Erwin Road, Room 1502, Box 3808, Durham, NC 27710. Received October 7, 2015; accepted October 8, 2015. Address correspondence to T.P.S.; E-mail: [email protected] duke.edu The author has not identified a conflict of interest. & SIR, 2015 J Vasc Interv Radiol 2015; 26:1803–1805 http://dx.doi.org/10.1016/j.jvir.2015.10.004

Figure 1. Ziv Haskal, MD, fifth editor of JVIR, January 2011 to the present.


JVIR Celebrates 25 Years of Innovation


evolution upon it.

Figure 2. The JVIR January 2011 cover showing the new cover design.

journals. This meant both a focus upon content and uniform presentation of content. Getting the content meant improving the authors’ experiences by efficient and meaningful communication and rapid publishing. Presentation meant enacting a vision for article length, expression style, etc. To reach tight, to-the-point, neutral, concise reporting as free as possible of undisclosed or unrecognized bias meant editing every paper to a line level—in an activist fashion. We delve into authors’ texts in detail. Researchers have accepted this, as our submissions have doubled. To maintain this, Dr. Haskal still edits every manuscript, even at current volumes. Equally, he doubled down on the “business” side of JVIR: defining data-driven operating procedures for submissions, goals for editors and author communication, and service to our advertisers and sponsors. This has allowed us to both manage the original submission volumes of 2011 when Dr. Haskal began in a fraction of the time and scale for double. He can see us handling a tripling. The goal has been to celebrate a specialty that is, daily, built upon the creativity and vision of its individuals treating patients in untested clinical waters. Equally, it is to help morph our current and next generation into practitioners who embrace data, instinctively sift it, and demand the highest levels of evidence. The






Over the past 25 years, there has been quite a change in the subject matter published in JVIR. Interventional oncology, unheard of in its first publication year of 1989, constituted 28.6% (2011), 33.2% (2012), 36.2% (2013), and 43.8% (2014) of laboratory and clinical studies and brief reports. Special or supplemental issues devoted entirely to interventional oncology were published in August 2013, July 2014, and July 2015. However, JVIR has remained committed to the wide interventional radiology subject breadth for which it has been recognized for the past 25 years with such publications as “Heparin-Bonded, Expanded Polytetrafluoroethylene– Lined Stent Graft in the Treatment of Femoropopliteal Artery Disease: 1-Year Results of the VIPER Trial” (February 2013), “The DENALI Trial: An Interim Analysis of a Prospective, Multicenter Study of the Denali Retrievable Inferior Vena Cava Filter” (October 2014), and “Paclitaxel-Coated versus Plain Balloon Angioplasty for Dysfunctional Arteriovenous Fistulae: One-Year Results of a Prospective Randomized Controlled Trial” (March 2015), to name only three. The variety of subject matter and its relative quantities were aptly displayed in Dr Haskal’s article “JVIR Clouds, Maps, and Data Visualization: What We Write and

Figure 3. The JVIR 25th anniversary cover.

Volume 26

Number 12




of the Society of Interventional Radiology (SIR) and Dr. Haskal closed this editorial with the following: Although interventional radiology retains those roots where it all began, where the need for daily ingenuity led to innovation (and case reports), it is also now the specialty that creates the prospective big-cohort quality research that changes health care on a large scale. Keep sending your papers.

Figure 4. Dr. Haskal and the JVIR 25th anniversary timeline at the SIR 2015 Annual Scientific Meeting.

Build upon—and a Plea for Better Views” (July 2013), which provides a graphic representation of publication and citation trends over time intervals. The past few years have also seen publications on controversial subjects, such as percutaneous angioplasty for chronic cerebral systemic venous insufficiency and catheterbased renal artery sympathectomy for hypertension, which showed early promise but have faded, at least at the time of this writing. Such is the price for residing in the ever-evolving field of interventional radiology. A January 2013 editorial, “The State of the Ship? The Vessel Is Sound” (4), reiterated the continued electronic growth, increasing submission rates, continued fast time to full print and average time to first decision for new manuscripts as well as the continued rise in impact factor. The year 2013 also marked the 40th anniversary

The authors responded with a record number of submissions in 2013, exceeding 1,000 for the first time since the inception of JVIR (and still increasing). Additionally, JVIR achieved the highest impact factor (2.409) of all interventional radiology journals in 2014, which is also the highest in the 25-year history of JVIR. Product advancement since 2011 has included the US Food and Drug Administration approval of the first carotid stent system (Acculink; Abbott Laboratories, Abbott Park, Illinois) in May 2011 and the first peripheral drug-eluting stent (Zilver PTX; Cook, Inc, Bloomington, Indiana) in November 2012. Education for future interventional radiologists has taken a radical turn over the past 4 years. In September 2012, the American Board of Medical Specialties approved interventional radiology as a primary specialty in medicine followed by the Accreditation Council for Graduate Medical Education Board of Director approval at its February 2013 meeting. In this year’s “Editor’s Annual Report: Strengthening the Core, Expanding the Range” (5), Dr Haskal noted: “As the Editor-in-Chief … I am proud to say that JVIR has provided me an extraordinary and ongoing opportunity for self-learning. I am very thankful for it. I hope you share my excitement.” How can one not be excited about JVIR? Its past reflects the accomplishments of so many, only a few of which have been briefly noted in this five-part series, which celebrates JVIR's 25th anniversary (Figs 3, 4). The first 25 years have taken JVIR from a three-part special series of the journal Radiology into its own as the premier interventional radiology journal. Our genuine excitement is unmistakably for what is yet to come.

REFERENCES 1. 2. 3. 4.

Haskal ZJ. JVIR: At the vanguard. J Vasc Interv Radiol 2011; 22:3–4. Haskal ZJ. 15. J Vasc Interv Radiol 2011; 22:739. Haskal ZJ. The JVIR iPad app debut. J Vasc Interv Radiol 2012; 23:1259. Haskal ZJ. The state of the ship? The vessel is sound. J Vasc Interv Radiol 2013; 24:1. 5. Haskal ZJ. Editor’s annual report: strengthening the core, expanding the range. J Vasc Interv Radiol 2015; 24:1–2.